US stock · Healthcare sector · Medical Devices
Company Logo

Abiomed, Inc.

ABMDNASDAQ

254.56

USD
+7.05
(+2.85%)
Market Closed
83.19P/E
45Forward P/E
4.30P/E to S&P500
11.615BMarket CAP
- -Div Yield

Abiomed, Inc.

NASDAQ:ABMD

RECENT
PRICE

254.56

P/E
RATIO

83.19

(PEG:-2.10)

P/E RATIO
RELATIVE
TO S&P

4.30

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.35 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 07/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Fiscal year

1.70

(1.15)

(0.48)

- -

1.87

(1.03)

(0.82)

- -

1.82

(1.26)

(1.01)

- -

2.10

(0.91)

(0.63)

- -

2.34

(0.52)

(0.25)

- -

2.72

(0.32)

(0.01)

- -

3.29

0.04

0.05

- -

4.04

0.38

0.60

- -

4.67

0.19

0.53

- -

5.67

2.80

0.94

- -

7.81

0.90

1.45

- -

10.30

1.21

1.50

- -

13.45

2.54

3.10

- -

17.13

5.77

4.64

- -

18.61

4.49

6.00

- -

18.78

5.00

4.90

- -

22.70

3.00

5.49

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.12

2.71

0.09

4.50

0.12

2.88

0.11

3.33

0.05

2.94

0.05

2.82

0.05

3.29

0.07

3.50

0.07

4.28

0.13

7.18

0.37

8.74

1.17

10.46

1.27

15.62

0.98

20.86

0.97

23.58

1.18

29.46

0.79

33.08

CAPEX per share

Book Value per share

26

27

32

35

37

37

38

39

39

41

42

43

44

45

45

45

45

Comm.Shares outs.(m)

(11.2)

(0.62)

- -

(12.4)

(0.72)

- -

(12.2)

(0.57)

- -

(9.4)

(0.13)

- -

(19.2)

(0.93)

- -

(46.7)

(2.87)

- -

515.7

34.68

- -

53.8

3.16

- -

146.1

8.05

- -

26.2

1.31

- -

114.9

5.18

- -

121.9

5.17

- -

132.4

5.30

- -

43.2

1.78

- -

51.9

1.37

- -

65.7

2.19

- -

95.0

4.91

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q4)

Total liabilities
$170 m.

Total assets
$1,673 m.

Long-term debt
- -

Cash and equiv.
$133 m.

Goodwill $77 m.

Retained earnings $965 m.

Common stock 46 m. shares

Market Capitalisation
$11,615 m. (as of 3/7/22)

101

(11.1)%

126

1.2%

158

10.5%

184

4.6%

230

12.4%

330

19.8%

445

20.2%

594

26.5%

769

29.2%

841

29.6%

848

27.1%

1,032

13.6%

Revenue (m)

Operating margin

4

(12)

4

1

3

15

3

7

3

114

3

38

6

52

11

112

14

259

20

203

24

226

28

137

Depreciation (m)

Net profit (m)

(8.2)%

(11.6)%

41.2%

1.2%

11.0%

9.5%

13.8%

4.0%

(295.2)%

49.4%

42.1%

11.6%

42.9%

11.7%

30.1%

18.9%

1.6%

33.7%

21.0%

24.1%

21.8%

26.6%

28.4%

13.2%

Income tax rate

Net profit margin

62

- -

105

88

- -

126

90

- -

137

88

- -

168

181

- -

292

242

- -

369

257

- -

452

410

- -

690

571

- -

937

504

- -

1,065

659

- -

1,330

838

- -

1,503

Working capital (m)

Long-term debt (m)

Equity (m)

(10.8)%

(8.3)%

(11.2)%

1.1%

1.7%

1.2%

10.5%

9.9%

11.0%

4.2%

4.2%

4.4%

38.0%

8.5%

39.0%

10.1%

15.5%

10.3%

10.8%

16.6%

11.5%

16.0%

20.4%

16.3%

27.3%

25.0%

27.6%

18.7%

21.1%

19.1%

16.5%

19.3%

17.0%

8.9%

11.4%

9.1%

ROIC

Return on capital

Return on equity

Working Capital

2020

2021

2022

Cash assets

443

483

384

Receivables

85

97

91

Inventory

90

81

94

Other

18

26

33

Current assets

636

788

976

Acc. Payable

33

35

35

Debt due

- -

- -

- -

Other

99

94

103

Current liab.

132

129

138

100.0%

- -

100.0%

- -

100.0%

(22.4)%

100.0%

64.9%

100.0%

2.1%

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

31.3%

100.0%

5.1%

Plowback ratio

Div.&Repurch. to FCF

Abiomed, Inc. (US) started trading on July 3, 1987 (cik: 0000815094), operates in the Healthcare sector (Medical Devices industry), has 2,003 full-time employees, and is led by Mr. Michael Minogue. Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

15.35%

23.83%

Cash flow

19.24%

36.27%

Earnings

20.23%

173.54%

Dividends

- -

- -

Book value

21.86%

31.67%

Insider trading

Type

Shares

Date

Plano Matthew T.

InKind

207

05/29/22

Plano Matthew T.

InKind

666

05/29/22

Plano Matthew T.

Award

1,500

05/29/22

Began Marc A

InKind

480

05/29/22

Began Marc A

InKind

976

05/29/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

208

205

222

207

841

2021

165

210

232

241

848

2022

253

248

261

270

1,032

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

1.97

0.29

1.53

0.70

4.49

2021

0.99

1.38

1.37

1.26

5.00

2022

(0.58)

1.25

1.01

1.33

3.00

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -